

Clinical trials of prolonged dual antiplatelet therapy

TrialResults-center www.trialresultscenter.org

1 stent

Trial	Treatments	Patients	Trials design and methods
prolonged dual antiplatelet therapy vs 12 months dual antiplatelet			
DES-LATE , 2010 [NCT00484926] n=1357/1344 follow-up: 19.2 mo	dual antiplatelet therapy (clopidogrel plus aspirin) versus aspirin alone	patients who had received drug eluting stents and had been free of major adverse cardiac or cerebrovascular events and major bleeding for a period of at least 12 months	Parallel groups open South Korea
DAPT <i>ongoing</i> [NCT00977938] n=20645 follow-up:	additional 18 months of thienopyridine treatment versus placebo	Subjects Undergoing Percutaneous Coronary Intervention With Either Drug-eluting Stent or Bare Metal Stent Placement for the Treatment of Coronary Artery Lesions	
OPTIMIZED <i>ongoing</i> n=NA	-	-	

More details and results :

- antithrombotics for stent in all type of patients at <http://www.trialresultscenter.org/go-Q151>
- dual antiplatelet therapy for stent in all type of patients at <http://www.trialresultscenter.org/go-Q578>

References

DES-LATE, 2010:

Park SJ, Park DW, Kim YH, Kang SJ, Lee SW, Lee CW, Han KH, Park SW, Yun SC, Lee SG, Rha SW, Seong IW, Jeong MH, Hur SH, Lee NH, Yoon J, Yang JY, Lee BK, Choi YJ, Chung WS, Lim DS, Cheong SS, Kim KS, Chae JK, Nah DY, Jeon DS, Seung KB, Jang JS, Park HS, Le Duration of Dual Antiplatelet Therapy after Implantation of Drug-Eluting Stents. N Engl J Med 2010 Mar 15;: [20231231] [10.1056/NEJMoa1001266](https://doi.org/10.1056/NEJMoa1001266)

DAPT, :

ongoing trial NCT00977938

Mauri L, Kereiakes DJ, Yeh RW, Driscoll-Shempp P, Cutlip DE, Steg PG, Normand SL, Braunwald E, Wiviott SD, Cohen DJ, Holmes DR Jr, Krucoff MW, Hermiller J, Dauerman HL, Simon DI, Kandzari DE, Garratt KN, Lee DP, Pow TK, Lee PV, Rinaldi MJ, Massaro JM Twelve or 30 Months of Dual Antiplatelet Therapy after Drug-Eluting Stents. N Engl J Med 2014 Nov 16;: [25399658] [10.1056/NEJMoa1409312](https://doi.org/10.1056/NEJMoa1409312)

OPTIMIZED, :

ongoing trial

2 percutaneous coronary intervention

Trial	Treatments	Patients	Trials design and methods
prolonged dual antiplatelet therapy vs 12 months dual antiplatelet			
DES-LATE , 2010 [NCT00484926] n=1357/1344 follow-up: 19.2 mo	dual antiplatelet therapy (clopidogrel plus aspirin) versus aspirin alone	patients who had received drug eluting stents and had been free of major adverse cardiac or cerebrovascular events and major bleeding for a period of at least 12 months	Parallel groups open South Korea
DAPT <i>ongoing</i> [NCT00977938] n=20645 follow-up:	additional 18 months of thienopyridine treatment versus placebo	Subjects Undergoing Percutaneous Coronary Intervention With Either Drug-eluting Stent or Bare Metal Stent Placement for the Treatment of Coronary Artery Lesions	
OPTIMIZED <i>ongoing</i> n=NA	-	-	

2

More details and results :

- antithrombotics for percutaneous coronary intervention in PCI with stent placement at <http://www.trialresultscenter.org/go-Q152>
- antiplatelets drug for percutaneous coronary intervention in all type of patients at <http://www.trialresultscenter.org/go-Q389>

References

DES-LATE, 2010:

Park SJ, Park DW, Kim YH, Kang SJ, Lee SW, Lee CW, Han KH, Park SW, Yun SC, Lee SG, Rha SW, Seong IW, Jeong MH, Hur SH, Lee NH, Yoon J, Yang JY, Lee BK, Choi YJ, Chung WS, Lim DS, Cheong SS, Kim KS, Chae JK, Nah DY, Jeon DS, Seung KB, Jang JS, Park HS, Le Duration of Dual Antiplatelet Therapy after Implantation of Drug-Eluting Stents. N Engl J Med 2010 Mar 15;: [20231231] [10.1056/NEJMoa1001266](https://doi.org/10.1056/NEJMoa1001266)

DAPT, :

ongoing trial NCT00977938

Mauri L, Kereiakes DJ, Yeh RW, Driscoll-Shempp P, Cutlip DE, Steg PG, Normand SL, Braunwald E, Wiviott SD, Cohen DJ, Holmes DR Jr, Krucoff MW, Hermiller J, Dauerman HL, Simon DI, Kandzari DE, Garratt KN, Lee DP, Pow TK, Lee PV, Rinaldi MJ, Massaro JM Twelve or 30 Months of Dual Antiplatelet Therapy after Drug-Eluting Stents. N Engl J Med 2014 Nov 16;: [25399658] [10.1056/NEJMoa1409312](https://doi.org/10.1056/NEJMoa1409312)

OPTIMIZED, :

ongoing trial